A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Vericel Corporation · NCT03588975
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 10–17 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 45
- US sites recruiting
- 11
- Study start
- October 24, 2018
- Record last updated
- October 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.
Being studied: MACI; microfracture
Conditions: Chondral Defect; Osteochondritis Dissecans (OCD); Articular Cartilage Defect; Articular Cartilage Disorder of Knee
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 10 to 17 years at the time of planned randomization
- Symptomatic cartilage or osteochondral defects
- One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).
- Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
- Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
- At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.
- Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.
- Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.
- Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.
- Written informed consent
Exclusion Criteria
- Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)
- Previous investigational drug or device use within 3 months prior to Screening
- Avascular necrosis of the target knee (other than potential OCD lesion to be treated)
- Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate
- ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion
- Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)
- Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint
- Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)
- Known history of septic arthritis in the index knee joint
- Current malignancy or treatment for malignancy within the past 5 years
- Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin
- Females who are pregnant or lactating
- Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:
- Any condition that has potential for negatively impacting intra or postoperative course
- Conditions that limit compliance with rehabilitation program
- Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function
- Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study
- Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance
Recruiting US locations
Stanford University School of Medicine
Palo Alto, CA 94304
Site contact: Amishi Jobanputra · 650-498-4180 · amishij@stanford.edu
Shriners Hospital for Children Northern California
Sacramento, CA 95817
Site contact: Kory Bettencourt · 916-453-5030 · kbettencourt@shrinenet.org
University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
Sacramento, CA 95817
Site contact: Julia Martin · 916-734-8175 · jyhmartin@health.ucdavis.edu
Ochsner Health System-Elmwood
New Orleans, LA 70121
Site contact: Joseph Laurent · 504-842-0263 · Joseph.laurent@ochsner.org
Johns Hopkins Hospital
Baltimore, MD 21224
Site contact: Rushyuan Jay Lee, MD · 443-997-2663 · rlee74@jhmi.edu
University of Michigan Medsport Orthopaedic Surgery
Ann Arbor, MI 48106
Site contact: Christopher Ray · 734-615-0934 · raychri@med.umich.edu
Akron Children's Hospital
Akron, OH 44308
Site contact: John Polousky, MD · 330-543-3500 · JPolousky@akronchildrens.org
The Ohio State University Jameson Crane Sports Medicine Institute
Columbus, OH 43202
Site contact: Jenna DeFranco · 614-293-2761 · jenna.defranco@osumc.edu
Penn Medicine University City
Philadelphia, PA 19104
Site contact: Dorothy Brill · 215-273-5062 · dcbrill@upenn.edu
The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
Philadelphia, PA 19104
Site contact: Divya Talwar · 215-590-1527 · talward@chop.edu
Children's Hospital of Wisconsin
Milwaukee, WI 53201
Site contact: John Erickson, DO · 414-337-7325 · JErickson2@childrenswi.org
Study contacts (from the official record)
- Vericel Clinical Affairs · 978-347-2876 · clinicalhotline@vcel.com
Similar studies in California
All mental health studies in California →- RecruitingHealthy volunteersEarly Phase 1
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
Neurosterix
- Location
- Los Alamitos, CA
- Eligibility basics
- Ages 18–55
- RecruitingPhase 1Overnight stay mentioned
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
Leal Therapeutics, Inc
- Location
- Los Alamitos, CA + 9 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 1Overnight stay mentioned
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
BioXcel Therapeutics Inc
- Location
- Anaheim, CA + 3 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingHealthy volunteersPhase 1
Inflammatory Challenge and Fear
University of California, San Francisco
- Location
- San Francisco, CA
- Eligibility basics
- Ages 18–65